Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A guide to the people and activist organizations who paved the way for Donald Trump's attacks on diversity practices in ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

LANSING, MI — Pharmaceutical giant Pfizer has agreed to pay $59.7 million plus interest to settle bribery allegations against ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Recent health news highlights various developments, including EssilorLuxottica's FDA clearance for Nuance audio glasses, WHO ...